TY - JOUR
T1 - Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy
AU - O'Donnell, Peter H.
AU - Jensen, Ana
AU - Posadas, Edwin M.
AU - Bridge, Julia A.
AU - Yeldandi, Anjana V.
AU - Yang, Ximing J.
AU - Stadler, Walter M.
AU - Al-Ahmadie, Hikmat
PY - 2010/2
Y1 - 2010/2
N2 - Background. A 42-year-old white man with no significant prior medical history presented with macroscopic hematuria of 2 months' duration. His family history was notable for a maternal grandfather with kidney cancer. Investigations. Urinalysis, CT, microscopic examination of tumor, immunohistochemical analysis of tumor, hemoglobin electrophoresis, molecular cytogenetic analysis, gene sequencing.Diagnosis. Renal medullary-like carcinoma in an adult without sickle cell trait, sickle cell disease or other hemoglobinopathies.Management. The patient underwent laparoscopic nephrectomy to remove the tumor and received adjuvant sorafenib (400mg per day) as part of the E2805 ASSURE (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma) trial. Metastatic recurrence of the tumor occurred 9 months after nephrectomy, for which the patient underwent tumor debulking and retroperitoneal lymph node dissection, followed by chemotherapy consisting of gemcitabine (2,000 mg/m 2) and doxorubicin (50 mg/m2), both given on day 1 of a 14-day cycle. After six cycles of drug treatment, the patient had achieved a partial response. The patient was managed by active surveillance for 4 months, when he developed further symptoms and disease progression was detected. Third-line systemic therapy in the form of 21-day cycles of cisplatin (80 mg/m2 on day 1) and etoposide (100 mg/m2 on days 1-3) has recently been initiated.
AB - Background. A 42-year-old white man with no significant prior medical history presented with macroscopic hematuria of 2 months' duration. His family history was notable for a maternal grandfather with kidney cancer. Investigations. Urinalysis, CT, microscopic examination of tumor, immunohistochemical analysis of tumor, hemoglobin electrophoresis, molecular cytogenetic analysis, gene sequencing.Diagnosis. Renal medullary-like carcinoma in an adult without sickle cell trait, sickle cell disease or other hemoglobinopathies.Management. The patient underwent laparoscopic nephrectomy to remove the tumor and received adjuvant sorafenib (400mg per day) as part of the E2805 ASSURE (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma) trial. Metastatic recurrence of the tumor occurred 9 months after nephrectomy, for which the patient underwent tumor debulking and retroperitoneal lymph node dissection, followed by chemotherapy consisting of gemcitabine (2,000 mg/m 2) and doxorubicin (50 mg/m2), both given on day 1 of a 14-day cycle. After six cycles of drug treatment, the patient had achieved a partial response. The patient was managed by active surveillance for 4 months, when he developed further symptoms and disease progression was detected. Third-line systemic therapy in the form of 21-day cycles of cisplatin (80 mg/m2 on day 1) and etoposide (100 mg/m2 on days 1-3) has recently been initiated.
UR - http://www.scopus.com/inward/record.url?scp=77049115709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77049115709&partnerID=8YFLogxK
U2 - 10.1038/nrurol.2009.255
DO - 10.1038/nrurol.2009.255
M3 - Article
C2 - 20145663
AN - SCOPUS:77049115709
SN - 1759-4812
VL - 7
SP - 110
EP - 114
JO - Nature Reviews Urology
JF - Nature Reviews Urology
IS - 2
ER -